NCT06988475
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06988475
Title DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations (DETERMINE)
Acronym DETERMINE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Cancer Research UK
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR


No variant requirements are available.